Ondansetron Tablets USP 8 mg + Ondansetron Hydrochloride
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Fasting State
Conditions
Fasting State
Trial Timeline
May 1, 2011 → Sep 1, 2011
NCT ID
NCT01578252About Ondansetron Tablets USP 8 mg + Ondansetron Hydrochloride
Ondansetron Tablets USP 8 mg + Ondansetron Hydrochloride is a phase 1 stage product being developed by Ipca Laboratories for Fasting State. The current trial status is completed. This product is registered under clinical trial identifier NCT01578252. Target conditions include Fasting State.
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01578252 | Phase 1 | Completed |
| NCT01578265 | Phase 1 | Completed |
Competing Products
20 competing products in Fasting State